independent controlled drug release. Drug Dev Ind Pharm 37(7):798–808


Claudio Camponeschi, Paolo Colombo. (EP 2283824 A1) Compositions and Formulations based on swellable matrices for sustained release of poorly soluble drugs such as Clarithromycin. Date of Patent February 16, 2011.


Dayer JM. 2010. Therapeutic targets in rheumatoid arthritis: The interleukin-6-Receptor, Rheumatology, pp 15-24


68 Frank Buttgereit. 2010. Low-Dose glucocorticoid chronotherapy of rheumatoid arthritis: 12 week efficacy data of 5 mg modified-release (MR) prednisone, Annals of Rheumatic Diseases, pp 220
69 Frank Buttgereit. 2010. Safety data for low-dose glucocorticoid chronotherapy of rheumatoid arthritis with 5 mg modified-release (MR) prednisone in a randomized, double-blind, placebo-controlled trial, Annals of Rheumatic Diseases, pp 219
70 Frank Buttgereit. 2009. Prednisone Chronotherapy of rheumatoid arthritis: sustained efficacy of a novel modified-release formulation over 12 months, Arthritis & Rheumatism, pp 409


drug delivery systems. AAPS PharmSciTech 1(3):E19


97 Hazel Judith Bardsley (US 6677326 B2) Corticosteroid Formulation Comprising Less Than 2.5 mg Prednisolone For Once Daily Administration. United States Patent. Published Date October 1, 2002.


125 Katayama H, Kanke M (1992) Drug release from directly compressed tablets
containing zein. Drug Dev Ind Pharm 18(20):2173–2184


Lynne Lamberg. 1996. Time of day medicine dose is taken may boost its efficacy, cut Toxicity, pp 1143-1144


150 Mitchell K et al (1993) The influence of drugs on the properties of gels and swelling characteristics of matrices containing methylcellulose or
hydroxypropylmethylcellulose. Int J Pharm 100:165–173


174 Perry MG, Kirwan JR, Jessop DS, Hunt LP. Overnight variations in cortisol, interleukin 6, tumour necrosis factor alpha and other cytokines in people with


Raymond C Rowe, Paul J Sheskey and Marian E Quinn., 2009. Handbook of


204 Smolen JS. 2010. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs, Annals of Rheumatic Diseases. pp 964-975


175


236 U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Drug Approval Reports


www.medicalnewstoday.com/articles/192363.php
www.medicines.org.uk LODOTRA® PIL and XPIL
www.arthritis.org/modified-release-prednisone.php
www.mskreport.com modified-release prednisone reduces morning stiffness
www.mskreport.com lodotra delayed-release prednisone aces phase III
www.mskreport.com Nitec grants german marketing rights to Merch pharma gmbh for Lodotra a modified-release low-dose Prednisone for RA
www.mskreport.com Efficacy of modified-release versus standard Prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1);
a double-blind, randomized controlled trial

www.clinicaltrials.gov Study to assess the safety and efficacy of Modified-release prednisone (LORDOTRA®) therapy in active rheumatoid arthritis patients (CAPRA-2)

www.UK Medicines Information.com Prednisone Modified Release Tablets

www.USPTO.gov


